Profound Medical Corp. (Nasdaq:PROF) is a medical technology company that develops and commercializes minimally invasive surgical tools and technologies for the ablation of cancerous tumors in the prostate gland. The company’s flagship product, TULSA-PRO, is an innovative, image-guided transurethral ultrasound ablation system that delivers precise and personalized prostate cancer treatment.
Comps: Beyond Air, Inc. (Nasdaq:XAIR), ZimVie Inc. (Nasdaq:ZIMV)
To begin with, it’s worth noting that all these companies recorded negative earnings. However, Profound Medical Corp. outshines its peers in several areas. For one, it possesses better earnings per share and net income figures than the competition. Additionally, its return-on-equity outperforms that of Beyond Air. Furthermore, Profound Medical Corp.’s profit margin is more favorable when compared to that of ZimVie.